End points and clinical trial designs in pulmonary arterial hypertension
- 1 June 2004
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (12) , S48-S55
- https://doi.org/10.1016/j.jacc.2004.02.010
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Beraprost therapy for pulmonary arterial hypertensionJournal of the American College of Cardiology, 2003
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJournal of the American College of Cardiology, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionAmerican Heart Journal, 2002
- Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trialJournal of the American College of Cardiology, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996